CEBPB and cancer: More interestingly, a higher expression of CEBPB could indicate a higher sorafenib resistance in 12 types of cancer in GDSC (liver hepatocellular carcinoma (LIHC), BRCA, CESC, COAD + READ, UCEC, STAD, MESO, PRAD, KICH + KIRC + KIRP, TGCT, THCA, and BLCA) (Supplementary Figs. S10D, E and S12A–L).